{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Non-Small+Cell+Lung+Cancer&page=9", "query": { "condition": "Advanced Non-Small Cell Lung Cancer", "page": 9 }, "page_size": 10 }, "pagination": { "page": 9, "page_size": 10, "total_count": 1842, "total_pages": 185, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Non-Small+Cell+Lung+Cancer&page=10&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Non-Small+Cell+Lung+Cancer&page=8&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-17T07:48:38.702Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04460456", "title": "A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HER2 Positive Solid Tumors" ], "interventions": [ { "name": "SBT6050", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" }, { "name": "Cemiplimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Silverback Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 58, "start_date": "2020-07-27", "completion_date": "2022-12", "has_results": false, "last_update_posted_date": "2022-06-30", "last_synced_at": "2026-10-17T07:48:38.702Z", "location_count": 6, "location_summary": "Boston, Massachusetts • Durham, North Carolina • Pittsburgh, Pennsylvania + 3 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04460456" }, { "nct_id": "NCT07241039", "title": "A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Squamous Tumors" ], "interventions": [ { "name": "ABBV-711", "type": "DRUG" }, { "name": "Budigalimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 220, "start_date": "2025-11-20", "completion_date": "2030-10", "has_results": false, "last_update_posted_date": "2026-08-19", "last_synced_at": "2026-10-17T07:48:38.702Z", "location_count": 6, "location_summary": "Duarte, California • Irvine, California • Chicago, Illinois + 3 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Huntersville", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT07241039" }, { "nct_id": "NCT04250545", "title": "Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leptomeningeal Neoplasm", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Malignant Neoplasm in the Brain", "Recurrent Lung Non-Small Cell Carcinoma", "Stage IV Lung Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8" ], "interventions": [ { "name": "Sapanisertib", "type": "DRUG" }, { "name": "Telaglenastat Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2020-10-26", "completion_date": "2026-11-21", "has_results": true, "last_update_posted_date": "2026-05-26", "last_synced_at": "2026-10-17T07:48:38.702Z", "location_count": 7, "location_summary": "Duarte, California • Irvine, California • Los Angeles, California + 2 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04250545" }, { "nct_id": "NCT04660929", "title": "CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HER2-positive", "Adenocarcinoma", "Bile Duct Cancer", "Biliary Tract Cancer", "Bladder Cancer", "Breast Cancer", "Breast Neoplasm", "Carcinoma, Ductal", "Carcinoma, Hepatocellular", "Cancer", "Lung Cancer, Non-Small-Cell", "Carcinoma, Ovarian Epithelial", "Carcinoma, Small Cell", "Carcinoma, Squamous", "Carcinoma, Transitional Cell", "Colorectal Cancer", "Esophagogastric Junction Neoplasms", "Inflammatory Breast Cancer", "Stomach Neoplasms", "Malignant Neoplasms", "Ovarian Neoplasms", "Pancreatic Cancer", "HER2-positive Solid Tumors", "HER2-positive Breast Cancer", "HER2-positive Gastric Cancer", "HER-2 Protein Overexpression", "HER-2 Gene Amplification", "Prostate Cancer", "Head and Neck Cancer", "Endometrial Cancer", "Lung Cancer, Small Cell" ], "interventions": [ { "name": "CT-0508", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Carisma Therapeutics Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2021-02-02", "completion_date": "2024-12-31", "has_results": false, "last_update_posted_date": "2024-12-18", "last_synced_at": "2026-10-17T07:48:38.702Z", "location_count": 7, "location_summary": "Duarte, California • Chapel Hill, North Carolina • Portland, Oregon + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Portland", "state": "Oregon" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04660929" }, { "nct_id": "NCT06545331", "title": "Study of XB010 in Subjects With Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locally Advanced or Metastatic Solid Tumors", "Esophageal Squamous Cell Cancer", "Head and Neck Squamous Cell Cancer", "NSCLC (Non-small Cell Lung Cancer)", "Hormone-receptor-positive Breast Cancer", "Triple Negative Breast Cancer (TNBC)" ], "interventions": [ { "name": "XB010", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Exelixis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 396, "start_date": "2024-08-06", "completion_date": "2027-10-20", "has_results": false, "last_update_posted_date": "2026-10-15", "last_synced_at": "2026-10-17T07:48:38.702Z", "location_count": 16, "location_summary": "Irvine, California • Los Angeles, California • Washington D.C., District of Columbia + 12 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Orlando", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06545331" }, { "nct_id": "NCT03101839", "title": "Phase I Dose-Escalation Study of AZD4785 in Patients With Advanced Solid Tumours", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Small Cell Lung Cancer", "Advanced Solid Tumours" ], "interventions": [ { "name": "AZD4785", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 28, "start_date": "2017-05-15", "completion_date": "2019-01-08", "has_results": false, "last_update_posted_date": "2019-10-04", "last_synced_at": "2026-10-17T07:48:38.702Z", "location_count": 3, "location_summary": "Sarasota, Florida • Boston, Massachusetts • Nashville, Tennessee", "locations": [ { "city": "Sarasota", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03101839" }, { "nct_id": "NCT03421353", "title": "AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumours" ], "interventions": [ { "name": "AZD9150", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "5-Flourouracil", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 76, "start_date": "2018-02-07", "completion_date": "2024-03-28", "has_results": false, "last_update_posted_date": "2024-08-21", "last_synced_at": "2026-10-17T07:48:38.702Z", "location_count": 6, "location_summary": "Lafayette, Indiana • Oklahoma City, Oklahoma • Nashville, Tennessee + 3 more", "locations": [ { "city": "Lafayette", "state": "Indiana" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Dallas", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03421353" }, { "nct_id": "NCT03386929", "title": "Survival Prolongation by Rationale Innovative Genomics", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer Metastatic", "Non-small Cell Lung Cancer Stage IIIB" ], "interventions": [ { "name": "Avelumab", "type": "DRUG" }, { "name": "Axitinib", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Worldwide Innovative Network Association", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2017-11-29", "completion_date": "2022-12-29", "has_results": true, "last_update_posted_date": "2023-12-18", "last_synced_at": "2026-10-17T07:48:38.702Z", "location_count": 2, "location_summary": "La Jolla, California • Sioux Falls, South Dakota", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Sioux Falls", "state": "South Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03386929" }, { "nct_id": "NCT05557045", "title": "A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancer", "Metastatic Cancer", "Solid Tumor", "Melanoma", "Non-small Cell Lung Cancer (NSCLC)", "Colorectal Cancer (CRC)", "Anaplastic Thyroid Cancer (ATC)" ], "interventions": [ { "name": "JZP815", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jazz Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 98, "start_date": "2022-10-10", "completion_date": "2028-04-01", "has_results": false, "last_update_posted_date": "2026-09-10", "last_synced_at": "2026-10-17T07:48:38.702Z", "location_count": 15, "location_summary": "Los Angeles, California • Denver, Colorado • Orlando, Florida + 10 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05557045" }, { "nct_id": "NCT00514293", "title": "Bexarotene, Tretinoin, and Combination Chemotherapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "bexarotene", "type": "DRUG" }, { "name": "capecitabine", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "tretinoin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Raghu Nandan, M.D., Inc", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2007-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-01-10", "last_synced_at": "2026-10-17T07:48:38.702Z", "location_count": 1, "location_summary": "Lakewood, California", "locations": [ { "city": "Lakewood", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00514293" } ] }